Stock AHEALTH APEX HEALTHCARE
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Apex Healthcare

Equities

AHEALTH

MYL7090OO003

End-of-day quote BURSA MALAYSIA
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
3.3 MYR -0.30% Intraday chart for Apex Healthcare +8.91% +32.53%
Apr. 15 Apex Healthcare Berhad Proposes the Special Dividend for the Financial Year Ended 31 December 2023 CI
Feb. 22 Apex Healthcare Boosts Dividend Despite Profit Decline in Q4 MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The company is in a robust financial situation considering its net cash and margin position.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • The company benefits from high valuations in earnings multiples.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
APEX HEALTHCARE Stock Apex Healthcare
+32.53% 499M -
MCKESSON CORPORATION Stock McKesson Corporation
+16.03% 70.45B
C+
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
+2.22% 25.03B
C+
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+7.11% 8.29B
B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
-2.98% 8.05B
C
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-20.55% 7.97B
B-
H. LUNDBECK A/S Stock H. Lundbeck A/S
+3.91% 4.62B
B-
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+17.12% 4.25B
B+
EBOS GROUP LIMITED Stock EBOS Group Limited
-1.24% 4.04B
B-
GALENICA AG Stock Galenica AG
-3.44% 3.86B
B
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. AHEALTH Stock
  4. Ratings Apex Healthcare